6.4 Nuclear receptors

Nuclear receptor structure

Nuclear receptors are a family of ligand-activated transcription factors that regulate gene expression in response to hormones, metabolites, and other signaling molecules. They share a common modular structure with several functional domains, each contributing to ligand recognition, DNA binding, and transcriptional control. This modular design is what makes them such versatile drug targets.

DNA-binding domain

• Highly conserved region that recognizes and binds specific DNA sequences called hormone response elements (HREs)
• Contains two zinc finger motifs that insert into the major groove of DNA, anchoring the receptor to its target sequence
• Determines which genes a given receptor will regulate and also plays a role in receptor dimerization

Ligand-binding domain

• Located at the C-terminus and responsible for binding specific ligands (hormones, metabolites, or synthetic compounds)
• Ligand binding triggers conformational changes that expose or hide surfaces for interaction with coactivators or corepressors
• Also contributes to receptor dimerization and contains the ligand-dependent activation function (AF-2), which drives transcriptional activation when a ligand is bound

Activation function domains

• Two distinct regions, AF-1 and AF-2, work together to activate transcription of target genes
• AF-1 sits in the N-terminal domain and functions independently of ligand binding. Its activity varies significantly between receptor subtypes.
• AF-2 resides within the ligand-binding domain and only becomes active upon ligand binding
• Both domains recruit coactivators and components of the transcriptional machinery to initiate gene transcription

Hinge region

• A flexible linker connecting the DNA-binding domain to the ligand-binding domain
• Allows the conformational flexibility needed for the receptor to adopt different functional states and recruit coregulatory proteins
• Contains nuclear localization signals (NLS) that direct the receptor's transport from the cytoplasm into the nucleus

Nuclear receptor signaling

Nuclear receptors translate extracellular chemical signals into changes in gene expression. The signaling pathway moves from ligand binding through receptor activation to the recruitment of coregulatory proteins that ultimately turn genes on or off.

Ligand binding and activation

1. A specific ligand (hormone, metabolite, or synthetic compound) enters the cell and binds the ligand-binding domain of the receptor.
2. Ligand binding induces a conformational change that causes the receptor to dissociate from chaperone proteins (such as heat shock proteins, in the case of steroid receptors).
3. The freed receptor translocates into the nucleus (if it wasn't already there), dimerizes, and binds to DNA response elements to regulate gene expression.

Not all nuclear receptors follow this exact sequence. Some, like thyroid hormone receptors, are already bound to DNA in the nucleus and switch from repression to activation upon ligand binding.

Coactivator and corepressor interactions

• Coactivators enhance transcription by facilitating chromatin remodeling (e.g., histone acetylation) and recruiting RNA polymerase II and associated factors
• Corepressors suppress gene expression by promoting a condensed chromatin state (e.g., histone deacetylation), making DNA less accessible
• The balance between coactivator and corepressor recruitment determines whether a target gene is turned on or off. This balance is what selective receptor modulators exploit therapeutically.

DNA response element binding

• Nuclear receptors bind hormone response elements (HREs) in the promoter or enhancer regions of target genes
• Each HRE consists of two half-sites (typically hexanucleotide sequences) arranged as direct repeats, inverted repeats (palindromes), or everted repeats
• The spacing and orientation of these half-sites dictate which receptor can bind. For example, estrogen receptors recognize inverted repeats spaced by 3 nucleotides (IR-3), while vitamin D receptors prefer direct repeats spaced by 3 nucleotides (DR-3).

Gene transcription regulation

• Once bound to an HRE, a nuclear receptor can either activate or repress transcription depending on the ligand and cellular context
• Activation involves coactivator recruitment, chromatin remodeling to an open state, and assembly of the transcriptional complex to initiate RNA synthesis
• Repression involves corepressor recruitment and chromatin compaction, blocking transcription
• The specific genes regulated depend on cell type, developmental stage, and which coregulatory proteins are expressed in that tissue

Types of nuclear receptors

The nuclear receptor superfamily is large and diverse. Classification is based on ligand specificity, DNA-binding properties, and physiological function.

Steroid hormone receptors

These receptors respond to steroid hormones and typically reside in the cytoplasm bound to chaperone proteins until ligand binding triggers nuclear translocation.

• Estrogen receptor (ER): mediates estrogen signaling in reproductive tissues, bone, and the cardiovascular system
• Progesterone receptor (PR): regulates uterine function and pregnancy maintenance
• Androgen receptor (AR): drives male sexual development and spermatogenesis
• Glucocorticoid receptor (GR): mediates cortisol's effects on metabolism, stress response, and immune suppression
• Mineralocorticoid receptor (MR): regulates sodium and potassium balance in the kidney

Thyroid hormone receptors

• Activated by thyroid hormones, primarily $T_3$ (the more active form) and $T_4$ (a prohormone converted to $T_3$ in tissues)
• Two main isoforms: TRα (predominant in heart and brain) and TRβ (predominant in liver and pituitary)
• Unlike steroid receptors, thyroid hormone receptors are typically bound to DNA even without ligand, actively repressing target genes until $T_3$ binds and switches them to activation
• Mutations in TRβ cause resistance to thyroid hormone (RTH) syndrome, where tissues respond poorly to thyroid hormones

Retinoid X receptors

• RXRs are unique because they serve as obligate heterodimeric partners for many other nuclear receptors, including RARs, PPARs, LXRs, FXR, and VDR
• Activated by 9-cis retinoic acid, though the physiological relevance of this ligand is debated
• By partnering with so many different receptors, RXRs act as central coordinators of multiple signaling pathways
• Involved in embryonic development, lipid metabolism, and glucose homeostasis

Peroxisome proliferator-activated receptors

Three subtypes with distinct tissue distributions and functions:

• PPARα: expressed mainly in liver, promotes fatty acid oxidation and ketogenesis
• PPARβ/δ: broadly expressed, involved in fatty acid metabolism and energy expenditure
• PPARγ: the master regulator of adipogenesis (fat cell formation) and a key enhancer of insulin sensitivity. This is the target of thiazolidinediones (rosiglitazone, pioglitazone), used to treat type 2 diabetes.

All three subtypes are activated by fatty acids and their derivatives.

Orphan nuclear receptors

• Nuclear receptors for which endogenous ligands have not been definitively identified or are still under investigation
• Examples include liver X receptors (LXRs) (cholesterol metabolites are now recognized as ligands), farnesoid X receptor (FXR) (bile acids), and pregnane X receptor (PXR) (xenobiotics)
• As ligands are discovered for "orphan" receptors, they get reclassified as "adopted" orphan receptors. LXR and FXR are good examples of this process.
• Many play important roles in metabolism, inflammation, and detoxification of foreign compounds

Ligands for nuclear receptors

The nature of the ligand determines the biological response and the therapeutic potential of targeting a given nuclear receptor.

Endogenous ligands

• Naturally occurring molecules that activate nuclear receptors under normal physiological conditions
• Key examples:
  • Steroid hormones: estrogen, testosterone, cortisol, aldosterone, progesterone
  • Thyroid hormones: $T_3$ and $T_4$
  • Vitamin D ($1,25\text{-dihydroxyvitamin D}_3$)
  • Fatty acid derivatives (for PPARs)
  • Bile acids (for FXR)
  • Oxysterols (for LXRs)
• Binding affinity and specificity of endogenous ligands for their cognate receptors are critical for maintaining normal physiology

Synthetic agonists and antagonists

• Chemically synthesized compounds designed to mimic (agonists) or block (antagonists) the action of endogenous ligands
• Selective estrogen receptor modulators (SERMs) like tamoxifen and raloxifene exhibit tissue-specific agonist or antagonist activity. Tamoxifen acts as an antagonist in breast tissue (useful in breast cancer) but as an agonist in bone (helps prevent osteoporosis).
• Synthetic glucocorticoids (dexamethasone, prednisone) are more potent and longer-acting than cortisol, widely used as anti-inflammatory and immunosuppressive agents

Selective receptor modulators

Selective receptor modulators represent a sophisticated pharmacological strategy. Rather than simply turning a receptor fully on or off, these compounds produce different effects in different tissues.

• SERMs and selective androgen receptor modulators (SARMs) are the best-known examples
• Their tissue selectivity arises because different cell types express different ratios of coactivators and corepressors. The same ligand-receptor complex can recruit different coregulatory proteins depending on the cellular context.
• The goal is to maximize therapeutic benefit (e.g., anti-tumor activity in breast) while minimizing side effects (e.g., preserving bone density)

Physiological roles of nuclear receptors

Nuclear receptors regulate a wide range of physiological processes. Their specific functions depend on tissue distribution, ligand availability, and the target genes they control.

Metabolism and energy homeostasis

• PPARα promotes fatty acid oxidation and ketogenesis in the liver during fasting
• PPARγ stimulates fat storage in adipose tissue and enhances insulin sensitivity in peripheral tissues
• LXRs regulate cholesterol efflux and fatty acid synthesis
• FXR controls bile acid synthesis and recycling, and also influences glucose homeostasis
• Dysregulation of these pathways contributes to obesity, type 2 diabetes, and dyslipidemia

Development and differentiation

• Retinoic acid receptors (RARs) and RXRs mediate the effects of retinoic acid on embryonic patterning, limb development, and organogenesis. This is why retinoid use during pregnancy is teratogenic.
• ER and AR are essential for the development of reproductive tissues and secondary sexual characteristics
• Vitamin D receptor (VDR) regulates calcium and phosphate homeostasis, bone mineralization, and cell differentiation in skin and immune cells

Reproduction and fertility

• Estrogen and progesterone signaling through ER and PR regulate ovarian function, the menstrual cycle, uterine receptivity, and mammary gland development
• Androgens acting through AR drive male reproductive development, spermatogenesis, and maintenance of secondary sexual characteristics
• Disruption of these pathways can cause reproductive disorders, infertility, and hormone-dependent cancers

Inflammation and immunity

• Glucocorticoids acting through GR suppress pro-inflammatory cytokines and chemokines, making them potent anti-inflammatory agents
• PPARγ agonists (thiazolidinediones) reduce inflammation and have been explored in conditions like psoriasis and ulcerative colitis
• LXRs and VDR modulate both innate and adaptive immune responses, with implications for autoimmune diseases and host defense

Nuclear receptors as drug targets

Because nuclear receptors sit at the intersection of ligand signaling and gene regulation, they are attractive targets for pharmacological intervention across many disease areas.

Therapeutic applications

Selective modulation strategies

• The goal is to design ligands that produce beneficial effects in target tissues while avoiding side effects in others
• This exploits the fact that coactivator/corepressor expression varies by cell type, so the same ligand can trigger different transcriptional outcomes in different tissues
• SERMs and SARMs are the most clinically advanced examples of this approach
• Selective modulation has the potential to broaden the therapeutic use of nuclear receptor-targeting drugs while improving their safety profiles

Challenges and limitations

• Nuclear receptor signaling is complex, and predicting tissue-specific effects of new ligands remains difficult
• Off-target effects can occur because many nuclear receptors share structural similarities in their ligand-binding domains
• Resistance to nuclear receptor-targeted therapies can develop through receptor mutations (e.g., AR mutations in castration-resistant prostate cancer) or alterations in downstream signaling
• Long-term safety requires careful evaluation, especially for chronic conditions. Prolonged glucocorticoid use, for example, causes osteoporosis, metabolic disturbances, and immunosuppression.

Methods for studying nuclear receptors

Several experimental techniques are used to investigate nuclear receptor structure, function, and regulation. These methods are also central to drug discovery efforts.

Ligand binding assays

• Assess binding affinity and specificity of ligands for nuclear receptors
• Radioligand binding assays use radiolabeled ligands to directly measure receptor-ligand interaction and determine dissociation constants ($K_d$)
• Fluorescence polarization and surface plasmon resonance (SPR) allow real-time, label-free monitoring of binding kinetics
• These assays are essential for identifying novel ligands and optimizing lead compounds

Reporter gene assays

1. A reporter gene (e.g., luciferase or GFP) is placed under the control of a promoter containing the nuclear receptor's response element.
2. Cells are transfected with this construct along with the receptor of interest.
3. When a test compound activates the receptor, it binds the response element and drives reporter gene expression.
4. Reporter activity (light output for luciferase, fluorescence for GFP) serves as a quantitative readout of receptor activation.

These assays are widely used to screen compound libraries for agonists, antagonists, and selective modulators.

Chromatin immunoprecipitation (ChIP)

ChIP maps the genome-wide binding sites of nuclear receptors and their coregulatory proteins:

1. Cells are treated with formaldehyde to crosslink proteins to DNA.
2. Chromatin is fragmented (by sonication or enzymatic digestion).
3. An antibody specific to the nuclear receptor (or coregulator) immunoprecipitates the protein along with its bound DNA fragments.
4. Crosslinks are reversed, and the enriched DNA is analyzed by PCR (targeted), microarrays (ChIP-chip), or high-throughput sequencing (ChIP-seq) to identify binding sites across the genome.

Structural biology techniques

• X-ray crystallography provides high-resolution structures of receptor domains, revealing how ligands fit into the binding pocket and how dimerization and DNA recognition occur
• NMR spectroscopy captures protein dynamics in solution and can identify conformational changes induced by different ligands
• Cryo-electron microscopy (cryo-EM) has become increasingly powerful for visualizing full-length nuclear receptor complexes and their interactions with chromatin, especially for complexes too large or flexible for crystallography

Nuclear receptor-related diseases

Dysregulation of nuclear receptor signaling contributes to a wide range of diseases. Understanding these connections guides the development of targeted therapies.

Endocrine disorders

• Resistance to thyroid hormone (RTH): mutations in TRβ reduce receptor sensitivity to $T_3$, causing compensatory increases in thyroid hormone levels with variable clinical features
• Androgen insensitivity syndrome (AIS): mutations in AR produce a spectrum of defects in male sexual development, from mild undervirilization to complete female external phenotype in XY individuals
• Familial glucocorticoid deficiency: mutations in the melanocortin-2 receptor (MC2R) or its accessory protein (MRAP) impair adrenal cortisol production

Cancer and nuclear receptors

• ER-positive breast cancer: estrogen signaling through ER drives tumor proliferation. Tamoxifen (a SERM) blocks ER in breast tissue and remains a cornerstone of treatment. Aromatase inhibitors reduce estrogen production as an alternative strategy.
• Prostate cancer: AR signaling fuels tumor growth. Androgen deprivation therapy is a mainstay for advanced disease, though castration-resistant prostate cancer can emerge when AR becomes hypersensitive or is activated by alternative ligands.
• Acute promyelocytic leukemia (APL): a chromosomal translocation creates a PML-RARα fusion protein that blocks myeloid differentiation. All-trans retinoic acid (ATRA) overcomes this block and induces differentiation of leukemic cells, representing one of the first successful targeted therapies in oncology.
• PPARs have also been implicated in various solid tumors and hematological malignancies, though their roles are complex and context-dependent.

Metabolic syndrome and diabetes

• PPARγ is a master regulator of adipogenesis and insulin sensitivity. Thiazolidinediones activate PPARγ to improve insulin sensitivity in type 2 diabetes.
• Loss-of-function mutations in PPARγ cause familial partial lipodystrophy, characterized by selective loss of subcutaneous fat and severe insulin resistance
• LXRs and FXR regulate cholesterol and bile acid metabolism, respectively. Modulating these receptors is being explored for dyslipidemia and non-alcoholic fatty liver disease (NAFLD).

Inflammatory and autoimmune conditions

• Glucocorticoids acting through GR remain among the most effective anti-inflammatory drugs for asthma, rheumatoid arthritis, and inflammatory bowel disease
• However, chronic glucocorticoid use carries significant risks: osteoporosis, hyperglycemia, adrenal suppression, and increased infection susceptibility
• PPARγ agonists show anti-inflammatory potential beyond their metabolic effects
• Developing dissociated GR ligands that retain anti-inflammatory activity while reducing metabolic side effects is an active area of research